Kirax
Bonita Springs
About Kirax
Kirax Corporation, a biopharmaceutical company, engages in acquiring, developing, and commercializing specialty care therapies to treat oncology, pain, inflammation, acute, and supportive care areas of unmet medical need. Its product pipeline includes AFP-464, an anti-cancer agent in patients with breast cancer; GGTI-2418, a synthetic peptidomimetic inhibitor of geranylgeranyltransferase I (GGTase I) that appears to induce apoptosis by down-regulating several pivotal oncogenic and tumor survival pathways; and GFB-204, a calixarene derivative that is an inhibitor of VEGFR and PDGFR tyrosine phosphorylation. The company licenses or acquires rights to compounds in various stages of clinical development, as well as in-market products. Kirax Corporation was formerly known as Tigris Pharmaceuticals, Inc. The company was founded in 2005 and is based in Bonita Springs, Florida.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $540.8K
- Last round: Series Unknown (Sep 2012)
- Website: kiraxcorp.com
- Phone: 2394445405
Industries & Categories
Biopharma, Biotechnology, Medical, Oncology
Canonical: https://fsome.com/organization/kirax-3002231 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.